Articles

Adapt or die

Cytel and Tourtellotte bring more predictability to adaptive trials
Written byJeffrey Bouley
| 3 min read

CAMBRIDGE, Mass.—Greater adoption of adaptive clinical trials may be around the corner now that Cytel Inc. and Wayland, Mass.-based Tourtellotte Solutions have integrated Cytel's DoseSim adaptive trial simulator and Tourtellotte's tcVisualize clinical trial supply chain simulator. Using Monte Carlo computational methods, they say, the joined products provide accurate simulation of the clinical supply and the randomization necessary to ensure more predictable, cost-effective adaptive trials.

This collaboration follows another one completed in April between the two companies, wherein tcVisualize was integrated with Cytel's FlexRandomizer to aid the design and implementation of innovative clinical trials, including adaptive trials. That product, however, deals with randomization alone and thus isn't a true simulator, notes Ed Tourtellotte, CEO of Tourtellotte Solutions.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.